Transcriptomics

Dataset Information

0

IL-6 signaling in CD8 T cells promotes resistance to anti-PD-L1 immunotherapy

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Mus musculus

PROVIDER: GSE199048 | GEO | 2022/11/04

REPOSITORIES: GEO

Json Xml

Similar Datasets

Unknown A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
| S-EPMC7190922 | biostudies-literature
Unknown Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion.
| S-EPMC7481212 | biostudies-literature
Unknown Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.
| S-EPMC5975601 | biostudies-literature
Unknown Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma.
| S-EPMC8073815 | biostudies-literature
Unknown Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade.
| S-EPMC5665063 | biostudies-literature
Unknown PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
| S-EPMC5873884 | biostudies-other
Unknown Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
| S-EPMC7820876 | biostudies-literature
Unknown ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation.
| S-EPMC8058344 | biostudies-literature
Transcriptomics PD-L1 checkpoint blockade promotes regulatory T-cell suppressive capacity underlying immunotherapy resistance
2023-06-12 | GSE176250 | GEO
Unknown Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors.
| S-EPMC5836064 | biostudies-other